Dupixent (dupilumab)

Numéro de dossier de l’APP: 23403

État des négociations:

Négociation envisagée

Indication(s):

Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

Promoteur/fabricant:

Sanofi Genzyme Canada

Numéro de projet de l’AMC:

SR0870-000

Lettre d’entente de l’APP:

Sans objet

Conclusion du processus de négociation:

Sans objet